CervoMed Inc.
CRVO
$9.49
$0.060.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.56% | -18.31% | -13.19% | 27.08% | 91.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.56% | -18.31% | -13.19% | 27.08% | 91.23% |
| Cost of Revenue | 35.42% | 71.90% | 148.18% | 186.08% | -- |
| Gross Profit | -593.19% | -525.33% | -1,249.95% | -1,102.00% | -128.11% |
| SG&A Expenses | 30.01% | 11.97% | 9.48% | -8.27% | 153.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.26% | 46.10% | 89.15% | 74.60% | 112.96% |
| Operating Income | -120.90% | -104.36% | -191.91% | -101.72% | -143.31% |
| Income Before Tax | -170.12% | -94.65% | -183.86% | -321.05% | -62.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -170.12% | -94.65% | -183.86% | -321.05% | -62.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -170.12% | -94.65% | -183.86% | -321.05% | -62.53% |
| EBIT | -120.90% | -104.36% | -191.91% | -101.72% | -143.31% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -162.66% | -38.01% | -104.38% | -184.03% | 90.32% |
| Normalized Basic EPS | -162.62% | -38.01% | -104.37% | -184.05% | 90.32% |
| EPS Diluted | -162.66% | -38.01% | -104.38% | 21.17% | 90.32% |
| Normalized Diluted EPS | -162.62% | -38.01% | -104.37% | -195.68% | 90.32% |
| Average Basic Shares Outstanding | 2.85% | 41.04% | 38.86% | 163.06% | 1,579.75% |
| Average Diluted Shares Outstanding | 2.85% | 41.04% | 38.86% | 131.05% | 1,579.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |